NovoCure (NVCR) Free Cash Flow (2014 - 2026)

NovoCure (NVCR) has reported Free Cash Flow for 13 consecutive years, with $1.2 million the latest figure, recorded in Q2 2026.

• Quarterly Free Cash Flow rose 105.68% year-over-year to $1.2 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$25.4 million (up 68.36% YoY) and the FY2025 annual result came in at -$75.7 million, down 9.32% from the prior year.
• Free Cash Flow rose to $1.2 million in Q2 2026 per NVCR's latest filing, from -$18.7 million in the prior quarter.
• Over the last five years, Free Cash Flow for NVCR reached as high as $16.7 million in Q3 2022 and fell as low as -$46.3 million in Q1 2025.
• A 5-year average of -$14.1 million and a median of -$15.9 million in 2024 frame the typical range for Free Cash Flow.
• Annual changes were most pronounced in 2022 — Free Cash Flow tumbled 7898.46% — and 2025, when it surged 4959.61%.
• Year by year, Free Cash Flow stood at -$10.1 million in 2022, then sank by 110.88% to -$21.4 million in 2023, then surged by 42.03% to -$12.4 million in 2024, then sank by 84.78% to -$22.9 million in 2025, then jumped by 105.31% to $1.2 million in 2026.
• According to Business Quant data, Free Cash Flow over the past three periods registered $1.2 million, -$18.7 million, and -$22.9 million for Q2 2026, Q1 2026, and Q4 2025 respectively.